Brought to you by 
Series C brings in $63mm for Ception; adds $14.7mm
31 May 2007
Executive Summary
Ception Therapeutics (focused on developing drugs for inflammatory, infectious, and vascular conditions) brought in $63mm with a Series C preferred stock financing led by Essex Woodlands Health Ventures, with additional participation from new and returning shareholders including Investor Growth Capital, MDS Capital, New Science Ventures, and Aperture Venture Partners.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in $63mm for Ception; adds $14.7mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice